IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP
Burzynski Research Institute Inc. BZYR
15 fiscal years on record · USD · FY2024 reported · SEC filings only
$0
$-1.4M
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 0.00
Revenue, FY2024 · full 15-year series below
Revenue $M
Net income $M
FY2024 · Revenue 0.0 · Net income -1.4
-2.5M-5.0M
201020132016201920222024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
·
ROE
Not applicable: equity was zero or negative in this period, so return on equity has no meaning.
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on assets-87818.0%
Return on capital employedNot available: we don't have total assets or current liabilities for this period.
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ | ◌ |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ | ◌ | ◌ | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ◌ |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.01 | −0.01 | −0.01 | −0.01 | −0.01 | −0.01 | −0.01 | −0.01 | −0.01 | −0.02 | −0.02 | −0.03 | −0.05 | −0.05 | −0.04 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % — not applicable: negative equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Shares out B | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 60 reconciliationsAUDITED
Reconciled in 15 of the 15 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onnot stated in the filings
Incorporated inDelaware
Fiscal year endsFebruary 28
SEC categorysmaller reporting company
Data on record since2010